

**Amendments to the Claims:**

This claim listing will replace all prior versions and listings of claims in the application:

**Claim Listing:**

- 1-19. (Cancelled)
20. (Currently Amended) An immunostimulatory oligonucleotide compound, comprising:  
an immunostimulatory dinucleotide of formula CpG, C\*pG, C\*pG\* or CpG\*, wherein C  
is a natural pyrimidine nucleoside, C\* is a non-natural pyrimidine nucleoside, ~~and~~-G is a  
natural purine nucleoside [[or]] and G\* is a non-natural purine nucleoside, and wherein p  
is an internucleotide linkage selected from the group consisting of phosphodiester,  
phosphorothioate and phosphorodithioate;  
  
a 3'-3' linkage; and  
  
one or two accessible 5' ends;  
  
provided that ~~the~~ when the immunostimulatory dinucleotide is CpG neither  
oligonucleotide sequence on opposite sides of the linker is ~~not~~ complementary to the *gag*  
or *tat* gene of HIV-1.
21. (Original) The immunostimulatory oligonucleotide compound of claim 20, which  
oligonucleotide comprises two accessible 5' ends.
22. (Canceled)
- 23-40. (Cancelled)
41. (New) The immunostimulatory oligonucleotide compound of claim 20, wherein G\* is 7-  
deazaguanosine.